Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Role of CD5-negative CD8+ T cells in adaptation to antigenic variation of human immunodeficiency virus type 1

Xin-Yun Zhang¹, Jian-Rong Zhao², Yi-Le Xue³, Ying-Kui Jiang¹, Wei-Min Jiang¹

¹Department of Infection, Huashan Hospital Affiliated to Fudan University, Shanghai 200040; ²Department of Medicine, Infectious Disease Hospital in Yunnan Province, Kunming 100142; ³Department of AIDS, Sexually Transmitted Diseases, Shanghai Municipal Center for Disease Control & Prevention, Shanghai 200336, China.

For correspondence:- Wei-Min Jiang Email: jiang7514@gmail.com Tel:+862152887953

Received: 5 January 2015 Accepted: 2 November 2015 Published: 27 December 2015

Citation: Zhang X, Zhao J, Xue Y, Jiang Y, Jiang W. Role of CD5-negative CD8+ T cells in adaptation to antigenic variation of human immunodeficiency virus type 1. Trop J Pharm Res 2015; 14(12):2207-2212 doi: 10.4314/tjpr.v14i12.8

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of 3-oxotirucalla-7, 24-dien-21-oic acid on CD8⁺ T cell recovery in human immunodeficiency virus type 1 (HIV-1) disease.

Methods: The increase in the rates of CD8⁺ T cells over 48 weeks following treatment with 3-oxotirucalla-7, 24-dien-21-oic acid was investigated. Plasma HIV-1 load was measured by Versant™ HIV-1 RNA 3.0 branched chain DNA assay while flow cytometry was used for blood CD4 cell counts. For the analysis of the data obtained, Stata version 9.0 was employed.

Results: 3-Oxotirucalla-7, 24-dien-21-oic acid treatment increased CD8⁺ T cell count from a median of 89 % at baseline to 99 % at 48 weeks. The proportion of patients with CD8⁺ T cell count < 90 % decreased from 50 % at baseline to 1 %. There was a similar rate of phase 1 CD8⁺ T cell recovery and greater rates of phase 2 recovery in patients with baseline CD8⁺ T counts < 50 cells/μL. Among those that achieved CD8⁺ T cell count > 500 cells/μL at 48 weeks, 23 % had baseline CD8⁺ T cell counts of < 50 cells/μL. However, the proportion of the patients that attained CD8⁺ T count of 200 cells/μL at 48 weeks was lower than those with higher baseline CD4 cell counts.

Conclusion: 3-Oxotirucalla-7,24-dien-21-oic acid treatment induces greater tendency for CD8⁺ T cell recovery in patients with baseline CD8⁺ T cell counts < 50 cells/μL during 48 weeks of treatment. Therefore, 3-oxotirucalla-7,24-dien-21-oic acid is a promising agent for CD8⁺ T cell count recovery in patients with HIV infection.

Keywords: CD8+ T cells, HIV infection, Oleanolic acid, Lymphocyte cell, Cell recovery